Latest melanomas Stories
A recently-published study in the journal Clinical Cancer Research supported by the Stand Up To Cancer (SU2C) charitable foundation has identified new molecular targets which could potentially result in new remedies for difficult-to-treat melanomas.
Researchers from UCLA's Jonsson Comprehensive Cancer Center led an international team of scientists in conducting two studies that provide critical insights into two important ways that tumors resist BRAF inhibitors.
Melanoma is the most deadly form of skin cancer, estimated by the National Cancer Institute to afflict more than 70,000 people in the United States annually and the incidence rate continues to rise.
The human body does a great job of generating new cells to replace dead ones but it is not perfect. Cells need to communicate with or signal to each other to decide when to generate new cells.
Physician-based screening for melanoma is associated with higher rates of detecting the cancer than self-examinations, according to this study.
Physician-based screening for melanoma is associated with higher rates of physician-detected melanoma and detection of thinner melanoma.
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.
A new report shows a follow-up program could help detect melanoma earlier in high-risk patients.
A follow-up program for patients at high risk of developing skin cancer appears to be associated with the detection of melanomas at early stages and with good prognosis.
- A hairdresser.